Skip to main content
Terug
CTMX logo

CytomX Therapeutics, Inc.

Datakwaliteit: 100%
CTMX
NASDAQ Healthcare Biotechnology
€ 4,46
▲ € 0,01 (0,22%)
Marktkapitalisatie: 759,03M
Dagbereik
€ 4,34 € 4,61
52-Weeksbereik
€ 0,40 € 8,21
Volume
4.402.975
50D / 200D Gem.
€ 5,24 / € 3,55
Vorige Slotkoers
€ 4,45

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -43,7 0,4
P/B 7,7 2,9
ROE % -35,3 3,7
Net Margin % -22,8 3,8
Rev Growth 5Y % 19,5 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue grew 19,54% annually over 5 years — strong growth
Earnings declined -154,50% over the past year
Debt/Equity of 0,04 — conservative balance sheet
Negative free cash flow of -75,81M
PEG of 0,24 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 64,36%

Groei

Revenue Growth (5Y)
19,54%
Revenue (1Y)-44,82%
Earnings (1Y)-154,50%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-35,25%
ROIC-14,21%
Net Margin-22,79%
Op. Margin-25,67%

Veiligheid

Debt / Equity
0,04
Current Ratio3,09
Interest Coverage0,00

Waardering

P/E Ratio
-43,70
P/B Ratio7,67
EV/EBITDAN/A
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -44,82% Revenue Growth (3Y) -13,23%
Earnings Growth (1Y) -154,50% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 19,54% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 76,20M Net Income (TTM) -17,37M
ROE -35,25% ROA -11,46%
Gross Margin 100,00% Operating Margin -25,67%
Net Margin -22,79% Free Cash Flow (TTM) -75,81M
ROIC -14,21% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,04 Current Ratio 3,09
Interest Coverage 0,00 Dividend Yield 0,01%
Valuation
P/E Ratio -43,70 P/B Ratio 7,67
P/S Ratio 9,96 PEG Ratio 0,24
EV/EBITDA N/A Dividend Yield 0,01%
Market Cap 759,03M Enterprise Value 750,61M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 76,20M 138,10M 101,21M 53,16M 37,31M
Net Income -17,37M 31,87M -569.000,0 -99,32M -115,87M
EPS (Diluted) -0,15 0,38 -0,01 -1,48 -1,26
Gross Profit 76,20M 138,10M 101,21M 53,16M 37,31M
Operating Income -19,56M 25,00M -6,48M -101,34M -116,04M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 151,57M 120,53M 201,79M 260,89M 339,41M
Total Liabilities 52,56M 120,99M 249,24M 346,64M 339,87M
Shareholders' Equity 99,01M -456.000,0 -47,45M -85,75M -459.000,0
Total Debt 4,24M 9,39M 13,97M 18,06M 21,67M
Cash & Equivalents 12,67M 38,05M 17,17M 193,65M 205,53M
Current Assets 143,92M 107,31M 182,94M 237,10M 310,30M
Current Liabilities 46,62M 85,77M 155,91M 152,61M 77,87M